

farzana Perwad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1428985/publications.pdf>

Version: 2024-02-01

17
papers

1,218
citations

840776

11
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

1288
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic Variants Associated With Mineral Metabolism Traits in Chronic Kidney Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3866-e3876.	3.6	3
2	Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. <i>Calcified Tissue International</i> , 2021, 108, 622-633.	3.1	26
3	Renal Dnase1 expression is regulated by FGF23 but loss of Dnase1 does not alter renal phosphate handling. <i>Scientific Reports</i> , 2021, 11, 6175.	3.3	0
4	Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. <i>RMD Open</i> , 2021, 7, e001714.	3.8	26
5	Adverse Consequences of Chronic Kidney Disease on Bone Health in Children. <i>Seminars in Nephrology</i> , 2021, 41, 439-445.	1.6	2
6	Association Between Chronic Kidney Disease and Mineral Bone Disease (CKD-MBD) and Cognition in Children: Chronic Kidney Disease in Children (CKiD) Study. <i>Kidney Medicine</i> , 2020, 2, 398-406.	2.0	8
7	Î±-Lipoic Acid (ALA) Improves Cystine Solubility in Cystinuria: Report of 2 Cases. <i>Pediatrics</i> , 2020, 145, e20192951.	2.1	10
8	Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1097-1099.	4.5	12
9	Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation. <i>Kidney International</i> , 2019, 96, 890-905.	5.2	56
10	Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 2416-2427.	13.7	229
11	Fibroblast Growth Factor 23 Expression Is Increased in Multiple Organs in Mice With Folic Acid-Induced Acute Kidney Injury. <i>Frontiers in Physiology</i> , 2018, 9, 1494.	2.8	33
12	Monogenic Causes of Proteinuria in Children. <i>Frontiers in Medicine</i> , 2018, 5, 55.	2.6	17
13	Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1989-1998.	4.5	64
14	Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule. <i>PLoS ONE</i> , 2015, 10, e0142924.	2.5	26
15	Vitamin D metabolism in the kidney: Regulation by phosphorus and fibroblast growth factor 23. <i>Molecular and Cellular Endocrinology</i> , 2011, 347, 17-24.	3.2	62
16	Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1Î±-hydroxylase expression in vitro. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F1577-F1583.	2.7	264
17	Dietary and Serum Phosphorus Regulate Fibroblast Growth Factor 23 Expression and 1,25-Dihydroxyvitamin D Metabolism in Mice. <i>Endocrinology</i> , 2005, 146, 5358-5364.	2.8	380